– Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies – – May provide real-time data on therapy response, support patient ...

– Report details the company's commitment to improving healthcare through the power of genetic information and discloses Environmental, Social and Governance initiatives for fiscal year 2023 – SAN ...

SAN FRANCISCO, July 22, 2024 /PRNewswire/ -- Invitae (OTC: NVTAQ), a leading medical genetics company, today announced the launch of its Unlock™ Behind the Seizure ® program, which provides accessible ...